Centre for Infectious Disease Research in Zambia (CIDRZ)   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Lusaka Zambia (2001)

Organization Overview

First Clinical Trial
2005
NCT00074425
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centre for Infectious Disease Research in Zambia | Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka | Centre for Infectious Disease Research, Zambia

Active Ingredients

Drugs in Phase 4 Trials (2)

engerix-b (1 trial)

ivermectin (stromectol) (1 trial)

Drugs in Phase 3 Trials (3)

human rotavirus, live attenuated (Rotarix) (4 trials)

procaine benzylpenicillin (novocaine) (1 trial)

tv p2-vp8 (1 trial)

Drugs in Phase 2 Trials (1)

pro 2000/5 (1 trial)

Drugs in Other Trials (2)

aciclovir (zovirax) (1 trial)

killed oral cholera vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Communicable Diseases (Phase 2)

Cross Infection (Phase 4)

Diarrhea (Phase 3)

Gastroenteritis (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

HIV Infections (Phase 2)

Infections (Phase 2)

Pneumonia (Phase 3)

Rotavirus Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 8